Rheumatoid Arthritis: A Novel Approach in Diagnosis and Treatment

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423(6937): 356–61.10.1038/nature0166112748655 Search in Google Scholar

2. Scot DL, Kingsley GH. Rheumatoid arthritis. Scot DL, Kingsley GH (eds). Inflammatory arthritis in Clinical Practice. London: Springer-Verlag; 2008. pp. 1-3110.1007/978-1-84628-933-0_1 Search in Google Scholar

3. Greenapple R. Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers. Am Health Drug Benefits. 2012; 5(2):83-92. Search in Google Scholar

4. Firestein GS. Rheumatoid arthritis. Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS (eds). Kelley’s Textbook of rheumatology, 6th ed ed. Philadelphia: W.B. Saunders Company; 2001. pp. 921-67. Search in Google Scholar

5. Bush M, Emery P. The aetiology and pathogenesis of rheumatoid arthritis. Hospital Pharmacist 2002; 9: 5-11. Search in Google Scholar

6. Smolen JS, Aletaha D. The burden of rheumatoid arthritis and access to treatment: a medical overview. Eur J Health Econ 2008;8 Suppl 2:39-4710.1007/s10198-007-0087-9 Search in Google Scholar

7. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008 22; 371(9617):987-97.10.1016/S0140-6736(08)60453-5 Search in Google Scholar

8. Bush M. Emery P. The aetiology and pathogenesis of rheumatoid arhtritis. Hospital Pharmacist 2002;9:5-11 Search in Google Scholar

9. Kremers HM, Gabriel SE. Epidemiology. Clair WSt, Pisetsky DS, Haynes BF (eds). Rheumatoid Arthritis. Philadelphia: Lipincott Williams&Wilkins, a Wolters Kluwer business.; 2004. pp. 1-11. Search in Google Scholar

10. Firestein GS. Rheumatoid arthritis. Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS (eds). Kelley’s Textbook of rheumatology, 6th Ed ed. Philadelphia: W.B. Saunders Company; 2001. pp. 921-67. Search in Google Scholar

11. Scott DL, Wolf F, Huizinga TWJ. Rheumatoid arthritis Lancet 2010;376:1094-1108 Search in Google Scholar

12. Schett G, Stach C, Zwerina J, Voll nR and Manger B. How Antirheumatic Drugs protect Joints From Damage in Rheumatoid Arthritis. Arthritis Rheum 2008;58 (10): 2936-294810.1002/art.2395118821703 Search in Google Scholar

13. McInnes I, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Immunol 2007;7: 429–42.10.1038/nri209417525752 Search in Google Scholar

14. Szekanecz Z, Besenyei T, Paragh G, Koch AE. Angiogenesis in rheumatoid arthritis. Autoimmunity. 2009; 42(7):563-7310.1080/08916930903143083291791919863375 Search in Google Scholar

15. Schett G, Kiechl S, Weger S, et al. High sensetivity C-reactive protein and risk for non traumatic fractures in the Bruneck study. Arch Intern Med 2006;54:702-10 Search in Google Scholar

16.Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis destruction or repair? Nat Clin Pract Rheumatol. 2008;4: 128-35 Search in Google Scholar

17. Jimenez-Boj E, Redlich K, Turk B, et al. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis J Immunol 2005;175:2579-88 Search in Google Scholar

18. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with inadequate response to metotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12-1910.3109/s10165-008-0125-1 Search in Google Scholar

19. American College of Rheumatology. The 2010 ACREULAR classification criteria for rheumatoid arthritis [Internet] Available at:http://www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp Last visited at 24.01.2011. Search in Google Scholar

20. Arnett FC, et al. ACR Clinical Classification Criteria for Rheumatoid Arthritis: arthritis Rheum 1988; 31: 315–24 Search in Google Scholar

21. Scott DL, Wolf F, Huizinga TWJ. Rheumatoid arthritis Lancet 2010;376:1094-1108 Search in Google Scholar

22.Myles PS, Troedel S, Boquest M and Reeves M. The pain Visual Analog Scale: Is It linear or Nonlinear? Anesth Analg 1999;89:1517-20 Search in Google Scholar

23. Dept. of Rheumatology. University Medical Centre. Nijmigen the Netherlands. Disease Activity Score In Rheumatoid Arthritis [Internet] Available at: http://www.dasscore.nl/www.das-score.nl/ Last visited at 24.01.2011 Search in Google Scholar

24. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244-57.10.1093/rheumatology/keg07212595618 Search in Google Scholar

25. ARAMIS: Arthritis, Rheumatism, and Aging Medical Information System. The Health Assessment Questionnaire [Internet] Available at: http://aramis.stanford.edu/HAQ.html Last time visited at 24.01.2011 Search in Google Scholar

26.Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997; 36(5):551-9.10.1093/rheumatology/36.5.5519189057 Search in Google Scholar

27. Kent PD, Matteson EL. Clinical Features and Differential Diagnosis. ST Clair EW, Pisetsky DS, Haynes BF (eds). Rheumatoid Arthritis. Philadelphia: Lipincot Williams & Wilkins.; 2004. pp. 11-25. Search in Google Scholar

28. Davidson A, Brigdes SL. Autoimmunity. ST Clair EW, Pisetsky DS, Haynes BF (eds). Rheumatoid Arthritis. Philadelphia: Lipincot Williams & Wilkins; 2004. pp. 197-210. Search in Google Scholar

29. Tanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J Intern Med. 2016;31(2):210-8.10.3904/kjim.2015.137477372926932398 Search in Google Scholar

30. Kobelt G, Kasteng F. Access to innvative treatments in rheumatoid arthritis in Europe. A report prepared for the Europian Federation of Pharmaceutical Industry Associations (EFPIA); 2009 Search in Google Scholar

31. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56: 1424–32.10.1002/art.2252517469099 Search in Google Scholar

32. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 124–34.10.7326/0003-4819-148-2-200801150-0019218025440 Search in Google Scholar

33. Choy EH, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005; 44: 1414–21.10.1093/rheumatology/kei03116030080 Search in Google Scholar

34. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta analysis of efficacy and safety. BMC Musculoskelet Disord 2008; 9: 5210.1186/1471-2474-9-52237724718419803 Search in Google Scholar

35. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 30;343(22):1586-93.10.1056/NEJM20001130343220111096165 Search in Google Scholar

36. Wienecke T, Gøtzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev. 2004;(1):CD003789.10.1002/14651858.CD003789.pub2873031914974037 Search in Google Scholar

37. Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12 (11):1-27810.3310/hta1211018405470 Search in Google Scholar

38. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewe R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 2014; 73: 3–5.10.1136/annrheumdis-2013-20431724072562 Search in Google Scholar

39. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009; 5(10):531-41.10.1038/nrrheum.2009.18219798027 Search in Google Scholar

40. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 (16)30173-8. 3: 3–5. Search in Google Scholar

41. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2015;74:1037-1044.10.1136/annrheumdis-2013-204769443133424550168 Search in Google Scholar

42. Furst DE, Emery P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford) 2014;53:1560-1569.10.1093/rheumatology/ket414413558224402580 Search in Google Scholar

43. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-2219.10.1056/NEJMra100496522150039 Search in Google Scholar

44. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581.10.1002/art.2758420872595 Search in Google Scholar

45. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492–509.10.1136/annrheumdis-2013-204573393307424161836 Search in Google Scholar

46. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-637.10.1136/ard.2009.123919301509920215140 Search in Google Scholar

47. Negrei C, Bojinca V, Balanescu A, et al. Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches. Exp Ther Med. 2016; 11(4):1177-118310.3892/etm.2016.3045481223227073419 Search in Google Scholar

48. Johnsen AK and Weinblatt ME. Methotrexate. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH (eds). Rheumatology, 6th edition ed. Philadelphia, PA: Mosby Elsevier; 2015. pp. 443-449.10.1016/B978-0-323-09138-1.00056-5 Search in Google Scholar

49. McInnes IB, Jacobs JWG, Woodburn J and van Laar JM. Treatment of rheumatoid arthritis. Bijlsma JW (ed). Eular Compendium on Rheumatic Diseases: BMJ Publishing Group and European League against Rheumatism; 2009. pp. 83-86. Search in Google Scholar

50. Battistone MJ and Williams HJ. Disease modifying antirheumatic drugs 3: methotrexate. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH (eds). Rheumatology., 4th edition ed. Philadelphia, PA: Mosby Elsevier; 2008. pp. 449 - 457. Search in Google Scholar

51. Cannon G, Sciff M, Strand V and Holden W: Hepatic adverse events and other toxicity during treatment with leflunomide, methotrexate, other disease-modifying antirheumatic drugs (DMARDs), and combination DMARD therapy: Comparison to NSAIDS alone and adjustment for comorbidities cathegory. Arthritis Rheum 46 (Suppl): Abs S357, 2002. Search in Google Scholar

52.O’Dell JR. Methotrexate, Leflunomide, and Combination Therapies. Ruddy S (ed). Kelley’s Textbook of Rheumatology. Philadelphia, PA: WB Saunders Company; 2005. pp. 906-910. Search in Google Scholar

53. Ostensen M, Forger F. Management of RA in pregnant patients. Nat Rev Rheumatol. 2009: 5: 382-9010.1038/nrrheum.2009.103 Search in Google Scholar

54. Saag K and Buttgereit F. Systemic glucocorticoids. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH (eds). Rheumatology, 6th edition ed. Philadelphia, PA: Mosby Elsevier; 2015. pp. 423 - 431. Search in Google Scholar

55. Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718-22.10.1136/ard.61.8.718 Search in Google Scholar

56. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007 24;(1):CD00635610.1002/14651858.CD006356 Search in Google Scholar

57. Ravindran V, Rachapalli S, Choy EH. Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford) 2009; 48: 807–11.10.1093/rheumatology/kep096 Search in Google Scholar

58. Bykerk V. Non immunosuppressive disease modifying antirheumatic drugs. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH (eds). Rheumatology, 6th edition ed. Philadelphia, PA: Mosby Elsevier; 2015. pp. 436 - 437. Search in Google Scholar

59. Janković SM. Lekovi koji deluju preko proinflamatornih citokina. Jankovic SM (ed). Farmakologija i toksikologija. Kragujevac: Medicinski fakultet u Kragujevcu; 2011. pp. 316-20. Search in Google Scholar

60. Capell HA, Madhok R, Porter DR, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis. 2007;66(2):235-41.10.1136/ard.2006.057133 Search in Google Scholar

61. Haraoui B. Leflunomide. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH (eds). Rheumatology, 6th edition ed. Philadelphia, PA: Mosby Elsevier; 2015. pp. 451-45. Search in Google Scholar

62. Capell HA and Madhok R. Disease modifying antirheumatic drugs 2: sulfasalazine. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH (eds). Rheumatology, 4th edition ed. Philadelphia, PA: Mosby Elsevier; 2008. pp. 437-445. Search in Google Scholar

63. Bykerk V. Non immunosuppressive disease modifying antirheumatic drugs. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH (eds). Rheumatology, 6th edition ed. Philadelphia, PA: Mosby Elsevier; 2015. pp. 436 – 437 Search in Google Scholar

64. Gordon DA and Klinkhoff AV. Second Line Agents. Ruddy S (ed). Kelley’s Textbook of Rheumatology. Philadelphia, PA: WB Saunders Company; 2005. pp. 877-899. Search in Google Scholar

65.O’Dell JR. Methotrexate, Leflunomide, and Combination Therapies.. Ruddy S (ed). Kelley’s Textbook of Rheumatology. Philadelphia, PA: WB Saunders Company; 2005. pp. 906 - 910. Search in Google Scholar

66. Keystone E and Haraoui B. Disease modifying antirheumatic drugs 4: leflunomide. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH (eds). Rheumatology, 4th edition ed. Philadelphia, PA: Mosby Elsevier; 2008. pp. 461-468. Search in Google Scholar

67. Rau R, Herborn G, Menninger H, Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a oneyear double-blind study in 174 patients. Rheumatology (Oxford). 2002; 41(2):196-20410.1093/rheumatology/41.2.196 Search in Google Scholar

68. Fleischmann RM: Biologic therapy in rheumatoid arthritis. Rheumatol News (suppl 1): 3-4, 2002 Search in Google Scholar

69. Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71: 1303–08.10.1136/annrheumdis-2011-200490 Search in Google Scholar

70. Fan PT, Leong KH. The Use of Biological Agents in the Treatment of Rheumatoid Arthjritis. Ann Acad Med Sinapore 2007;36:128-34 Search in Google Scholar

71. National Institute for Health and Clinical Excellence. Nice clinical guideline 130. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis 2010. Available at www.nice.org.uk/TA130 last visited at 21. 10. 2010. Search in Google Scholar

72.National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 195. Adalimumab, eternecept, infliximab, rituximab and abatacept for the treatment for rheumatoid arthritis after the failure of a TNF inhibitor 2010. Available at www.nice.org.u Fleischmann RM: Biologic therapy in rheumatoid arthritis. Rheumatol News (suppl1): 3-4, 2002k/guidance/TA195 last visited 21.10.2010. Search in Google Scholar

73. Ramiro S, Gaujoux-Viala C, Nam JL, et al Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73: 529-535.10.1136/annrheumdis-2013-204575 Search in Google Scholar

74. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68(7):1136-45.10.1136/ard.2008.091025 Search in Google Scholar

75. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.10.1136/ard.2008.105197 Search in Google Scholar

76. Kaufmann J, Feist E, Roske AE and Schmidt WA: Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol. 2013;32: 1347-135510.1007/s10067-013-2281-8 Search in Google Scholar

77. Choi EH. T cell costimulation and other directed therapies. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH (eds). Rheumatology, 6th edition ed. Philadelphia, PA: Mosby Elsevier; 2015. pp. 468 - 470. Search in Google Scholar

78. Caporali R, Bugatti S, Cavagna L, Antivalle M, Sarzi-Puttini P. Modulating the co stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment? Autoimmun Rev. 2014;13(1):49-53.10.1016/j.autrev.2013.06.008 Search in Google Scholar

79.Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28-3810.1002/art.37711 Search in Google Scholar

80. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology(Oxford). 2001;40(2):205-1110.1093/rheumatology/40.2.205 Search in Google Scholar

81. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 17;350(25):2572-81.10.1056/NEJMoa032534 Search in Google Scholar

82. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, doseranging trial. Arthritis Rheum. 2006;54(5):1390-40010.1002/art.21778 Search in Google Scholar

83.Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-81010.1136/annrheumdis-2015-208840 Search in Google Scholar

84. Flint J, Panchal S, Hurrell A, et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016 10.pii: kev404.10.1093/rheumatology/kev404 Search in Google Scholar

85.Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very lowdose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(11):3371-8010.1002/art.21421 Search in Google Scholar

86. Verschueren P, De CD, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 2015; 74: 27–34.10.1136/annrheumdis-2014-205489 Search in Google Scholar

87. de Jong PH, Hazes JM, Han HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with lowdose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014; 73: 1331–39.10.1136/annrheumdis-2013-204788 Search in Google Scholar

88. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016; 68: 1–25.10.1002/acr.22783 Search in Google Scholar

89.Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, et al Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381–90.10.1002/art.21405 Search in Google Scholar

90. Burmester GR, Rigby WF, van Vollenhoven RF et al Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016; 75(6):1081-91..10.1136/annrheumdis-2015-207628 Search in Google Scholar

91.Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381: 1541–50.10.1016/S0140-6736(13)60250-0 Search in Google Scholar

92. Kostić M, Jovanović S, Tomović M, Milenković MP, Janković SM. Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from Serbia, country in socioeconomic transition. Vojnosanit Pregl. 2014;71(2):144-810.2298/VSP1402144K Search in Google Scholar

93. Jankovic SM, Kostic M, Radosavljevic M, Jovanovic S. Costs of rheumatoid arthritis in Balkan country (Serbia). E Eur Polit Soc. 2009; 23:135-8 93. Drummond M. Pharmacoeconomics: friend or foe? Ann Rheum Dis. 2006;65 Suppl 3:iii44-7 Search in Google Scholar

94. Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordström D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015 17;10(3):e0119683.10.1371/journal.pone.0119683 Search in Google Scholar

95. D’Aura Swanson C, Paniagua RT, Lindstrom TM, Robinson WH. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat Rev Rheumatol 2009;5:317-24.10.1038/nrrheum.2009.82 Search in Google Scholar

96. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, Mc-Innes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66: 311–28.10.1146/annurev-med-051113-024537 Search in Google Scholar

97. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377–86.10.1056/NEJMoa1310476 Search in Google Scholar